Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Bonesupport, Audiocast, Q3'26

By Inderes10/22/2026, 8:00 AM
Bonesupport

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Torbjörn Sköld
00:01 - 12:37

Thank you. Operator. Welcome, everyone, to BONESUPPORT. BONESUPPORT Q3 2026 Results call. My name is Torbjörn Sköld, CEO of BONESUPPORT. With me here today is our Chief Financial Officer and our Chief Medical Officer, Dr. Michael Diefenbeck. Together, we will use the next 30 minutes to guide you through the Q3 presentation and then open the line for questions. Slide two, please. Before starting the presentation, I would like to draw your attention to the disclaimers covering any forward-looking statements. We will make today. So, let's look at the financial and operational highlights of the quarter. Q3 reflected solid execution across the business. Net sales came in at 409 million SEK, corresponding to a growth at constant exchange rates of 38% versus Q3 2025; reported growth was 39%, showing that the currency impact on our figures for the quarter has decreased compared to previous quarters. Our adjusted operating result, excluding incentive program effects, was 139 million SEK, corresponding to an adjusted operating margin of 34%. Reported operating result was 123 million SEK. We saw another quarter of solid cash generation, with operating cash flow reaching 138 million SEK after accounting for the ongoing share buyback program. This resulted in a cash position of 510 million SEK at quarter end after a period of significant commercial investments. It's encouraging to see the strong operating margin, together with the continued strong cash flow, as confirmation of the scalability of our business model. We continue to see strong traction for CERAMENT in the US, with sales reaching 288 million SEK for the quarter, compared with 192 million SEK in Q3 2025. In Europe and the rest of the world, we saw solid momentum across all markets and segments, with a growth of 34% at constant exchange rates compared to Q3 2025. The most important event of the quarter was the publication of the SOLARIO study in the New England Journal of Medicine. The study shows that the duration of systemic antibiotic treatment can be reduced significantly without compromising treatment outcomes. When local antibiotic therapy is used as part of the surgical treatment. Dr. Michael Diefenbeck will give an overview of what this study shows and why we believe it is a very important milestone and a game changer for patients. Important progress was made in the regulatory process for CERAMENT within the framework of the De Novo process. The supplemental data package requested by the FDA was submitted in September. If granted market authorization, CERAMENT will constitute an entirely new product category, much like CERAMENT was in 2022. Just as in the review of the de novo application for CERAMENT, both the Center for Drug Evaluation and Research and the Center for Devices and Radiological Health are involved, and the lead review team, which sits under CDER, remains the same as during the 510(k) process. The dialogue with the agency is constructive, and we look forward to the continued review in Q4. US CMS confirmed improved reimbursement for the use of CERAMENT in orthopaedic infection surgery, and more specific identification codes for CERAMENT G and CERAMENT V once approved by FDA. Progress on CERAMENT with antibiotics for spine continues to be solid. The CERAMENT launch is on track, and the preparations for the studies on antibiotic-eluting CERAMENT follow plan, an important step as we continue expanding our portfolio of indications and applications. Now, let's move on to the sales development. The chart shows total. Last 12 months reported sales in Swedish krona by quarter since 2019. In stacked bars per region and product category. As you can see, the launch momentum for CERAMENT in the US is strong, and EUROW has accelerated in the last five quarters. Given that we keep bringing new, strong clinical studies and opening up new market segments and new indications, a product like CERAMENT will remain in launch phase for many years to come. However, throughout 2025 and in the first half of 2026, we have seen a strong influence from the US dollar to Swedish krona depreciation, which influences the optics of the graph but not the in-market performance. As you will see in slides later in the presentation. Last 12 months growth in Q3 of 25% in the graph corresponds to an even stronger 31% at constant exchange rates. US CERAMENT LTM sales were flat year over year at constant exchange rates. In total, antibiotic-eluting CERAMENT grew by 39% LTM at constant exchange rates. US sales amounted to 344 million SEK, representing growth of 39% at constant exchange rates. We continue to experience strong growth of CERAMENT, driven by both increased access through new accounts and new surgeons, as well as wider adoption among existing users. We see growth from all three prioritized market segments: foot and ankle, trauma, and arthroplasty. In Q3, the US CMS, Center for Medicare and Medicaid Services, confirmed its proposed ruling. The full year 2027 IPPS (Inpatient Prospective Payment System) includes changes that improve payments for the use of CERAMENT in the treatment of orthopedic infections, such as periprosthetic joint infections, fracture-related infections, and diabetes-related bone infections. More severe injuries result in higher reimbursement, and regardless of severity, the hospital can use the highest codes when claiming reimbursement. This means that moderately severe conditions receive the same high reimbursement as when complicated injuries are treated. Note that this uplift applies only when CERAMENT is used in line with the label. CMS confirmed the introduction of more specific procedure and identification codes for CERAMENT G and CERAMENT V, consistent with the company's submission. This is very positive for BONESUPPORT as it validates the uniqueness and value CERAMENT brings and reduces potential barriers for using CERAMENT in daily clinical practice. CMS ties the extra reimbursement specifically to on-label use of approved products in this category, where BONESUPPORT currently holds the only approval. Strengthening our competitive moat. We have launched a rollout plan with supporting education and communication materials to fully capitalize on the ruling. The ruling came into effect on October 1st, 2026. The initial and early feedback we have received from surgeons and administrators is very positive, and we expect it to substantially strengthen the case for broader and deeper use of CERAMENT in existing and new accounts. As part of our ambition to modernize an outdated standard of care in the US, we have opened one market segment after another, starting with foot and ankle, followed by trauma. Now moving into revision arthroplasty, interest continues to grow for CERAMENT in revision arthroplasty and periprosthetic joint infections, where the clinical needs remain substantial and the evidence supporting our antibiotic-eluting technology has resonated strongly with surgeons. We have built a solid foundation for our spine strategy over the past quarters. By establishing distributor coverage and preparing the market, the surgeon access and early stages of adoption in spine follow plan and indicate the strength and potential of this segment, as this is a new clinical segment for us. More clinical data is needed to support broader market penetration. Importantly, the performance of CERAMENT in spine will help confirm the value proposition for the CERAMENT platform, which will pave the way for future antibiotic-eluting CERAMENT launches. Now let's turn to Europe and the rest of the world. Sales in EUROW came in at 64 million SEK, representing 34% growth at constant exchange rates. While part of this reflects a softer comparison base in Q3 2025 and also initial orders from a distributor change in Australia and New Zealand. It was still a very strong quarter. We saw strong development across our three market structures: direct, hybrid, and distributor markets. This model is well suited to the early stage. The company's operations in our direct markets, including the UK and Germany, delivered solid growth across the board. Our investments in hybrid markets developed well, underlying continued potential ahead. During the quarter, we entered into a distribution partnership with Stryker for Australia and New Zealand, which contributed 3.8 million SEK to sales through a couple of initial start-up orders. The partnership strengthens our presence in the region and gives us a good basis to continue developing these markets. Our distributor markets showed strong growth, and we see large potential to increase our footprint by increasing penetration in the countries in which we have a presence, as well as the potential to enter more countries. The SOLARIO study was published the evening before the start of the Joint Congress of the European Bone and Joint Infection Society (EBJIS) and the US Musculoskeletal Infection Society (MSIS). MSIS in Porto. It was featured in several presentations and scientific discussions. The response to SOLARIO reinforces our view that a paradigm shift is taking place and that local antibiotic therapy will play an increasingly important role in the treatment of orthopaedic infections. SOLARIO has the potential to be an important catalyst for changing the standard of care and treatment protocols worldwide for the benefit of patients, healthcare providers, and society, not least in antibiotic stewardship. Now, for a deeper scientific and clinical perspective on SOLARIO, I will now. I will now hand over to our Chief Medical Officer, Dr. Michael Diefenbeck.

Dr. Michael Diefenbeck
12:39 - 17:36

Thank you. Torbjörn. My name is Dr. Michael Diefenbeck. I am the Chief Medical Officer at BONESUPPORT. After some anticipation, the SOLARIO trial was published on September 16. SOLARIO stands for Short or Long Antibiotic Regimes in Orthopaedics. The study was published in the New England Journal of Medicine. One of the highest-ranked journals in medicine. First author is Professor Martin McNally, and senior author is Dr. Mette Scarborough, both from Oxford, England. You are probably familiar with the background. Orthopaedic infection is usually managed with surgery, local antibiotics, and prolonged systemic antibiotic therapy. And exactly this prolonged systemic antibiotic therapy was the focus of this study. The research question was: can the duration of systemic antibiotic therapy be limited to less than seven days, provided local antibiotics are used? The second objective was to determine if there is an advantage of local antibiotic therapy in terms of adverse events or side effects. This is a multicentre, open-label non-inferiority trial. Adults who had undergone surgery and implantation of a drug-device combination product, including antibiotics, were randomly assigned to receive post-operative systemic antibiotic therapy for either a long duration of more than four weeks or a short duration of less than seven days. The primary outcome parameter is treatment failure by 12 months, assessed according to protocol-defined criteria by a clinical endpoint committee whose members were unaware of the trial group assignments and who were not involved in the treatment of the patient. Next slide, please. Here are the results of the trial. 500 patients were randomized and 475 were assessed in the primary analysis. The primary outcome parameter, defined as treatment failure, occurred in 14.1% of the long-duration group and only 11.1% of the short-duration group, which met the pre-specified non-inferiority margin. This means that the short duration was non-inferior to the long duration. Next slide. And here are the results of the secondary outcome parameter. By week six after surgery, symptoms potentially related to the treatment had occurred in 45.2% of the patients in the long duration group, and only in 17.2% in the short duration group. This was a significant difference on the graph. You can see that there is a huge difference, especially in the severe and moderate adverse events. This means that the shorter duration of systemic antibiotic therapy is much more patient-friendly than the long duration of treatment. Slide ten, please. The authors of the study came to the following conclusion. Among patients who had undergone orthopedic surgery and received local antibiotics, a short course of systemic antibiotics was noninferior to a long course with respect to definite treatment failure by 12 months. So what do these results mean in the bigger picture? The World Health Organization declared at the end of 2019 that antimicrobial resistance is one of the ten most urgent global health threats, along with, for example, HIV, climate change and Ebola. To reduce antimicrobial resistance, or perhaps more accurately, the development of antimicrobial resistance, the WHO. defined six points. Number one. Shorten the duration of therapy. SOLARIO has clearly shown that this is possible. Number two, improve compliance in patients. The device-drug combination product, including antibiotics, is implanted directly into the bone, so there is nothing to worry about regarding compliance. The patient cannot remove the antibiotic. And on the other hand, they do not need to be constantly reminded to take the medication. Number three. Narrow antimicrobial choice. Indeed, mainly gentamicin and vancomycin were used. Number four. Avoid underdosing. A high antibiotic concentration is delivered by the local antibiotics. Number five. Improved targeting. The antimicrobials are exactly at the right spot. They are implanted directly into the bone. And finally, number six. Reduce the total antimicrobial burden. In the study, that was a saving of 6.4 kilograms, not grams, per 100 patients. And with this summary, I hand over to Håkan Johansson, BONESUPPORT CFO, for the financials.

Håkan Johansson
17:36 - 23:17

Thank you, Michael. Net sales improved from 294 million to 409 million, equalling a growth of 39% in reported sales and a growth of 38% in constant exchange rates. Torbjörn has already spoken about the performance in both the EUROW and the US, and the major drivers behind the sales growth. But as a large currency movement in US dollars hides the true trajectory in the US, I would like to share the US sales performance for CERAMENT in US dollars. CERAMENT is the growth driver in the US, and this slide shows the quarterly CERAMENT sales in the US in US dollars, with continued solid performance and a strong sequential growth in this quarter, both in net sales for the quarter and in net sales per workday. The contribution from the US segment improved by 60.2 million versus Q3 2025 and amounted to 171.4 million. The improved contribution relates to increased sales, net of the effect of increased costs. Selling and marketing expenses during the quarter amounted to 152.3 million, compared with 153.6 million in the previous year, of which sales commissions to distributors amounted to 111.4 million, compared with 85.1 million in the same quarter last year. From the graph at the bottom of the screen showing net sales as bars and gross margin as the orange marker. It can be noted that the gross margin remains stable and strong at 94% in EUROW and Rest of World. A contribution of 9.9 million was reported, compared with 12.5 million the previous year. Selling and marketing expenses increased by 6.4 million, mainly related to the previously communicated commercial investments in the EUROW booster program. From the lower graph and the orange marker, a minor movement in gross margin can be noted, mainly impacted by market mix. Selling expenses, excluding sales commission and fees, increased by 12.7 million compared with the previous year. Following commercial investments in both the US and Europe, investments aimed at future sales growth are driven both by market opportunities and by sustained high marketing activity. R&D expenses reflect a continued high activity level focused on strategic initiatives such as the market authorization submission for CERAMENT in the US, research and studies in spine and future portfolio innovation; and finally, administrative expenses, excluding the effects from the long-term incentive programs, remained stable with an increase of 2.5 million compared with the previous year. The adjusted operating result amounted to 139.3 million, with only minor currency effects impacting. This is something I will come back to in a later slide. Gross margin levels returned after a temporary dip in the previous quarter, following inventory write-downs in the second quarter. The difference between the adjusted and operating result is cost related to our long-term incentive programs, amounting to an expense of 15.9 million in the quarter, compared with an expense of 13.7 million in the previous year. As you could see on the previous slide, the increase in expense includes mainly an unfavorable share price development in the period. Operating cash flow was strong in the quarter and cash position closed at 510.5 million SEK. Despite the current share buyback program initiated in September and partially executed during the quarter, it impacted the period with 60 million SEK. During the quarter, the Swedish krona has continued to weaken against the US dollar, with only minor exchange gains and losses reported as other operating income and expenses. This graph on this slide shows, with grey bars, how the relationship between the US dollar closing rate and the Swedish krona has varied over time. This is read out on the axes. The blue dotted line, read out on the left Y-axis, shows the adjusted operating result. The adjusted operating result, excluding translation exchange effects, is the orange line and provides a more comparable view of the underlying trend. In the table below the graph, you can see the adjusted operating margin of 32.9% in the quarter, compared with 28.6% in the same quarter last year. From the second half of 2025 and early 2026, the operating margin has been impacted by the commercial investments made in both Europe and the US, and this quarter shows a return to gradually improved operating margins. A solid cash conversion has been reported continuously since Q3 2024, with an average cash conversion of 83% visible at the dotted line in this graph, and Q3 reported a solid cash flow and cash conversion of close to 100%. And with this, I hand back over to Torbjörn.

Torbjörn Sköld
23:20 - 24:53

Thank you and thank you, Dr. Michael Diefenbeck. To summarize, Q3 2026 sales grew by 38% at constant exchange rates, reflecting steady and consistent progress. US growth was 39% and EUROW grew. Growth was 34%. The adjusted operating margin was 34%, and the cash flow was solid, allowing us to buy back shares and still end the quarter with a cash position of north of half a billion SEK. Important clinical and regulatory milestones in the quarter were the publication of the SOLARIO trial, the confirmation of CMS increased reimbursement for CERAMENT G, and the submission of the complete data package to answer FDA's questions related to the CERAMENT De Novo submission. Following combined growth of 33% in constant currencies over the first three quarters, We confirm our previously communicated full-year outlook of sales growth between 33% and 36% in constant currencies. The quarter confirms that the company's position has strengthened and continues to be characterized by low but rapidly increasing market penetration, creating significant room for expansion for many years to come. Now let's open the line for questions.

Operator
24:55 - 25:12

If you wish to ask a question, please dial the pound key and then five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Filip Ekengren from Nordea. Please go ahead.

Filip Ekengren
25:14 - 25:39

Thank you, operator, and good morning all. So US CERAMENT increased substantially quarter-over-quarter, with incremental growth from Q2 and new customer recruitment described as rather stable across the indications. Could you provide a breakdown? How much of the acceleration comes from increased usage among existing surgeons, and perhaps also in which indications, please?

Torbjörn Sköld
25:40 - 26:38

We do not publicly disclose those numbers. But what we can say is that we see solid growth across all three segments: foot and ankle, trauma, and arthroplasty. We can also say that in all of the three segments, we see a good, healthy balance between the two drivers, meaning new accounts as well as increased usage. Of course, taking into account the effect that foot and ankle. That is the segment where we have been active and have worked for several years. Trauma is somewhat newer. And then arthroplasty is the newest. But we're very pleased. We are very pleased with the growth across the segments as well as by the growth type. That is about as much as we can disclose on it. Filip. I apologize. We don't disclose more numbers than that.

Filip Ekengren
26:40 - 27:01

No, I appreciate that. On CERAMENT, if and when approved, how much of the initial opportunity will come from patients or surgeons it cannot currently reach with CERAMENT versus perhaps switching existing procedures to V? Can you provide some insight into what your European experience suggests for the future?

Torbjörn Sköld
27:03 - 28:59

So, our European experience—why is the European experience relevant? It is because we have had both products available in the market for several years. The European experience indicates that our product mix of all the CERAMENT G and V products that we sell is approximately 70% to 75% G, with the remaining 25% to 30% being V. G and V products that we sell, around 70 to 75% of that is G and the remaining is V. That is our product mix. That is our starting point and starting assumption for the US. Now there are indications that we see in the US market. And this is not anything new for this quarter. We have seen it for several quarters. And we have raised this publicly several times; there seems to be a tendency or a preference in the US more weighted on V than G. Now, how much of that is based on science versus tradition or history. That remains to be debated. But our starting point is that we expect to see the US come to a similar mix as we've had in Europe. And then we'll see. But it is clear that US surgeons want and need CERAMENT V, and we expect the cannibalization to be limited. But there might be some, but clearly CERAMENT is expected to be a solid incremental driver of the growth case in the US. I hope that answers the questions, Philip.

Filip Ekengren
29:01 - 29:20

Thank you very much. And then perhaps a final one for me, squeezing it in with Q3 growth at 38% and guidance unchanged at 33% to 36%. What assumptions distinguish the lower and upper ends here? Do you expect the CMS changes to influence growth already in Q4? Or is that more of a 2027 play?

Torbjörn Sköld
29:23 - 29:25

I will leave that to Håkan.

Håkan Johansson
29:25 - 30:00

Thank you. No. Again, I do not think that we should include a material impact from the CMS already in Q4. So the guidance is more related to continued commercial execution on existing baselines. And again, we have seen volatility in sequential growth in the past and will continue to see that as well. It relates more to the guidance. It more relates to continued and, in many terms, normalized commercial execution.

Torbjörn Sköld
30:00 - 31:37

And on CMS, I apologize, I missed that you related the question to CMS. So on CMS, what we have seen—and we saw this at the Orthopaedic Trauma Association in Phoenix—is that there is significant momentum. US surgeons and the ones that we have talked to are very positive towards this ruling. And also the initial conversations that we have had with administrators are also very positive. So it is definitely going to help us and it is definitely strong ammunition for us, especially in the conversations related to when hospitals and administrators simply think that, well, it is a very expensive product and we get a lot of invoices on CERAMENT and why do you need that? So, then of course, the CMS ruling is very, very helpful. Having said that, it is also very clear that it is not just something that we can communicate to our surgeons, administrators, and hospitals in a single month. We expect this ruling to be an important topic for us in the coming quarters. It is very positive. We are well positioned for the growth journey ahead, not only with CERAMENT G, but also with CERAMENT V, which is actually also included in this ruling.

Filip Ekengren
31:40 - 31:42

Perfect. Thank you very much. I will get back into the queue.

Operator
31:44 - 31:48

The next question comes from Matthias from CIB. Please go ahead.

Matthias Thorn
31:50 - 32:11

Hi. Thanks for taking my questions. First one, just a follow-up on your comment regarding the incremental reimbursement for CERAMENT in the US. And I think you said you do not rely on any help from that in Q4. But why would it not help? Are you just being cautious on that end? Or if I am misunderstanding, I am sorry.

Unknown 1
32:12 - 32:12

If I catch.

Matthias Thorn
32:12 - 32:13

If I caught it in the wrong way.

Håkan Johansson
32:15 - 32:56

Thank you, Matthias, and it is good that you are asking the question. And what I said is, I don't expect this to have a material impact on the revenue in Q4. Of course, it will be helpful and it is helpful in terms of continuing to develop both adoption and access in the US over time. So we are very happy to have this CMS ruling, but I don't think that anyone should exaggerate the impact in the very short term. So we will make sure that this is a tool in our toolbox that we are using wisely in building the market.

Matthias Thorn
32:57 - 33:23

Thanks. Thanks for that. And also, staying on the same note, in Q2 we talked about the growth dynamics for a bit. I have touched on it before, but the communication was quite clear around that too. So, how has that developed since then? And also, do you think this incremental reimbursement can change that picture? That is my next question.

Torbjörn Sköld
33:24 - 36:27

Yeah. Good. So, go-stop-go. That you referred to, Mathias, was something that we saw in Q2. But in all transparency, we have seen the dynamics of go-stop-go for many quarters previously. So it is a natural part of the business that we are in. And we see it on a clinician level and we see it also on an administrative level. And what we mean by that is on a clinician level, when they are first exposed to CERAMENT, and especially CERAMENT G and V, the surgeons typically want to try it on a relatively narrow indication. It occurs periodically. A select group of patients. Of patients, they try it and then they watch these patients. So they begin. They use it in a couple of cases. And then they stop and evaluate whether it has the clinical impact and the clinical results that they want to see; if they're pleased with the results, they go again. So hence, this go-stop-go dynamic exists at a clinician level. It is relatively common. It is very common. We can also see it on the administrative level in a hospital or in a hospital group, and even on an IDN level in the US. And that is pretty much the same dynamics that we see on the clinician level, meaning that surgeons in the hospital start using the product and then as they use more, they reach a certain level of value that the hospital purchases. Then, they are typically flagged to the buyers and the administrators. And if the surgeons and the hospital, as well as us, have not done the work to prepare the administrators, the buyers, and the purchasers regarding what CERAMENT G and V are, then there could be these effects that we not only saw in Q2, but have seen previously. So there you have this stop on a hospital level. And then the approach is simply that we go and talk to the administrators and the value analysis committees about the value of CERAMENT G and CERAMENT V. So the go-stop-go pattern, both on a clinician level as well as an administrative level, has been there for years. We expect it to continue. We saw some of it in Q2, we continued to see it in Q3, and we expect to see it in Q4 as well as next year. So it is part of the business. But of course, Mathias, to your point, having the ammunition with the CMS ruling makes it a fantastic tool. It is probably the ideal tool to use in that type of conversation. And it really helps strengthen our case in those conversations.

Matthias Thorn
36:30 - 37:01

Thanks. Very clear. Then my last question is, based on the trajectory you see in trauma patients now, do you believe a market share similar to diabetic foot ulcers is possible, or will the long-term market share potential in foot always be higher? You believe. I appreciate that we cannot see into the future. You cannot either. But are there any insights regarding the feedback and the uptake so far? Yeah.

Unknown 1
37:02 - 37:04

Yeah. No, great question.

Torbjörn Sköld
37:04 - 38:30

What I can reference is simply the fact that a couple of weeks ago, we were at the Orthopaedic Trauma Association in Nashville, US. That was right after the SOLARIO publication. That was right after the CMS ruling. And of course, it is only trauma docs there. There is not a lot of foot and ankle or diabetes specialists there. Doctors there. I don't see any reason why we wouldn't be able to reach the same type of penetration in trauma as we've done in foot and ankle. Not at all. And having said that, in foot and ankle, we are still just scratching the surface. Yes. We have reached higher penetration and we have been at it for many, many more years. But I don't see any reason why we should be more or less bullish on trauma than we are on foot and ankle. The big question is, of course, how long will it take? But this is the beauty of BONESUPPORT that time is on our side. And the first principle that we always use is that you have to convert surgeon by surgeon, and you have to do it face to face. You don't do it with a study only. You don't do it with an email because these products are implanted in patients. We remain very bullish on trauma as we have done previously as well. So, no change on that. Yes.

Matthias Thorn
38:31 - 38:32

Thank you so much.

Operator
38:35 - 38:40

The next question comes from Sten Gustafson from ABG Sundal Collier. Please go ahead.

Sten Gustafson
38:42 - 39:27

Good morning. A number of questions, but I will try to limit it to looking at the CMS ruling, I suppose it is for hospital. It only applies to inpatient and not outpatient, perhaps that sort of clarification. And secondly, if you could perhaps tell us your mix between hospital versus outpatient, I am trying to figure out how much of your business will benefit from these improved reimbursements.

Torbjörn Sköld
39:29 - 40:37

Yes. So, thank you. Stan. First question. Yes, the ruling is only inpatient. And that simply stems from how it is set up and how it is named. So it is called the fiscal year 2027 IPPS, the inpatient prospective payment system. So this ruling relates to inpatient. The majority of our sales is currently in inpatient settings. Inpatient, there is some in outpatient, but to a large extent, it is only inpatient. So it relates to that, and of course, you know, how fast and how much the hospitals will use it. Time will tell, but we look very positively at this ruling and it will have a positive impact for us in the quarters to come. And we have good reasons to believe that the ruling will stay in place a year from now. And then all the work that we do now, in the coming years, it will, of course, help us in the long term as well. I hope that answers your questions.

Sten Gustafson
40:38 - 41:08

Absolutely. Thank you very much. And when it comes to the NTAP, I remember you had this, and while it was obviously temporary, you gained it on another segment. Have you noticed? Have you noticed a drop in usage among the doctors where the NTAP sort of disappeared after the three-year period?

Torbjörn Sköld
41:09 - 41:10

Not at all.

Sten Gustafson
41:13 - 41:42

Very good. In terms of your organization in the U.S. I mean, it looks like given the improved reimbursement, you have a good opportunity here to capture a lot of growth. Will you invest in more salespeople or how are you going to reach out to all these hospitals?

Torbjörn Sköld
41:43 - 43:26

Very good and relevant question. So when we're growing in the US 30-40%, then of course, we will need to continue to invest in our commercial organization. Including sales. But you bring up a very relevant point. And it comes to the fact that we. Have just as a company started to step into this somewhat more mature phase where it's not only about the classical sales, that's still the core. And that's still very important to be in front of orthopaedic surgeons and to be in front of the infectious disease specialists. So we are not going to slow down on that. That is going to be continued. But the point that you bring up is that these kind of conversations when it comes to the CMS ruling, of course the surgeons are important, but even more important are the administrators, however they are defined and whichever titles they might have. And that really depends. So in that area. We have invested and we are continuing to invest simply to make sure that we have the scale, the breadth, and the depth in our organization. So that is an area that we have already invested in. We are bringing on more people with a slightly different profile than the classical clinical sales. So that is an area where we have seen investments already done. And we're going to accelerate that in the coming quarter as well as in the next year.

Sten Gustafson
43:27 - 43:30

Perfect. Thank you very much. I will get back to the queue.

Operator
43:31 - 43:36

The next question comes from Eric Cassel from Danske Bank. Please go ahead.

Eric Cassel
43:38 - 44:10

Hi. Good morning. I had a question on the guidance as well as a follow-up to Philip. As he said, you know, the 33% to 36% guidance basically implies anywhere between 32% to 44% growth in Q4. Do you view the full range as possible? Still. I want to press you a bit on what you think are the factors to get you to either down towards 32% or up to 44%. Do you have any opinions on what is more likely in this range?

Torbjörn Sköld
44:11 - 45:26

Thank you, Eric. I mean, we provide the guidance simply because we think that is where we might end up, and that is why we provide it. So we think it is likely to end up anywhere in that range. Otherwise, we would not have provided it. So, that is the first part to your second question: what will it take? Well, it's very much the same that took us to deliver what we delivered in Q3, meaning that we continue to drive new accounts and to increase the penetration in existing accounts, that we do it in the US as well as EU, and we do it in all three segments: foot and ankle, trauma, and Arthroplasty. And then we, of course, will not provide sub-guidance to the guidance that we've already provided. The guidance is that we will end up for the year between 33% and 36%. We focus more on the long term and we are very pleased with the Q3 performance. We look very positively toward Q4. But we built this business for the long term, not just for it to hit one quarter or the next quarter.

Eric Cassel
45:27 - 45:47

Okay. Fair enough. And it looks like the product has started to stabilize a bit more here in Q3. Would you say that we have reached the stabilization point that you discussed back in Q1 and that it can now start to grow again? Or are there still expectations from your side regarding that?

Unknown 1
45:48 - 45:49

Sorry, could you repeat the beginning of your question?

Torbjörn Sköld
45:49 - 45:52

Beginning of the question because I missed that one. Sorry.

Eric Cassel
45:53 - 46:19

Oh yes. Yes, of course. It looks like the US market has started to stabilize. It is only down 2% now, compared to down 14% in Q2. So you talked about stabilization back in Q1. And then for it to return to growth, if I recall correctly, would you say that we have reached that stabilization point now and that we are looking towards growth again? Regarding the product in the US?

Håkan Johansson
46:20 - 47:26

I think that is what we have seen. And those are the numbers we shared; when we look at the last 12 months, CERAMENT BVF has been relatively flat. And in a way, that is quite very much in line with our expectations. Are we reaching that inflection point where we will start to grow again long-term? We don't expect huge growth from the CERAMENT BVF. It will, as we've seen outside the US, in Europe. Rest of world is growing slowly, in line with the overall market. The main focus will be on CERAMENT G and, hopefully around the corner, on CERAMENT V. And what we've said, and that still stands, is that with an extending customer base, we also see more surgeons using CERAMENT BVF. But again, it is not anything that will have a material impact or, if I put it that way, accelerate CERAMENT BVF growth. Now, the main focus for any investor should be to follow and see how CERAMENT G and eventually CERAMENT V perform in the US.

Eric Cassel
47:27 - 47:59

Okay. Thank you. And lastly for me for now, the 3.8 million from Stryker. Was that a one-off stocking order to sort of get them going? And what are your forecasts for the quarterly run rate from them in Q4? Is that likely going to be a much bigger account than the previous two that you have? Are the gross margin setups different compared to the previous hybrid model that you were under?

Torbjörn Sköld
48:00 - 49:17

Excellent question. So, yes, you are right. These were two startup orders to get going. We have seen operations through this, both in Australia as well as in New Zealand. So it is really nice. It is early days, but it is a really nice startup. We don't provide guidance on a country level, but we're very pleased with the fact that we get. Faster and better access to the total potential of Australia and New Zealand with a phenomenal player in this industry. So of course we are doing it because we believe we can do it faster than with the previous setup that we had; on your second question regarding the margins for us, this is as close to a standard contract as you could have. So from a contractual and margin level, it is very similar to the contracts with the distributors and hybrid markets that we already have.

Eric Cassel
49:19 - 49:20

Okay, great. Thank you so much.

Operator
49:24 - 49:27

The next question comes from Ed Hall from Stifel. Please go ahead.

Ed Hall
49:29 - 49:57

Good morning guys. Thanks for taking my questions. Most of them have been largely asked, but I think maybe just going back to the reimbursement side, if we were to put ourselves in the shoes of the hospital administrators. What is the timeline and the aspects that they need to undergo before they can start to get this updated billing flowing through their P&L. So, what is the timeline or lag that would need to happen? That would be my first question.

Unknown 1
49:59 - 50:00

Yeah. I mean,

Torbjörn Sköld
50:00 - 51:04

The ruling has been in effect as of October 1st. So it is open now. So as long as they have been trained, they know what to do. They know how to code the surgeries and which surgeries to pay extra attention to. Everything else is set up, but it is also about making sure that you get access to the right people, inform them about what it means, and how to do it. It is not very complicated. It is just that they use the same software and the groupers that they are used to. It is just making sure that they are informed about it. Some hospitals will move very fast, while some will probably take a bit longer. But what is very interesting to see when we have done the analysis on a hospital basis, is that when we use the hospital's own historical patient volumes, it is a no-brainer to use it.

Unknown 1
51:04 - 51:06

But to.

Torbjörn Sköld
51:06 - 51:12

To make someone understand that it is a no-brainer. There is a process to get there.

Ed Hall
51:13 - 51:33

Absolutely. I guess what I'm trying to understand is when we had the NTAP payments, there was a certain number of hospitals that either didn't acknowledge or understand that the payment was available. Would it be fair to assume that this obviously is a broader code? It is more widely used. So that issue that you have had historically may not be an issue going forward.

Torbjörn Sköld
51:37 - 52:24

I think the way that you should see it is that some hospitals will jump very fast on this, especially the ones that are on top of their operations. They are on top of their case mix. They are on top of their P&L. And what drives profit and what does not drive profit. I think those hospitals are easier to convince, the ones that are not, let's call it, as focused or as operationally savvy. It will take time. It is hard for us to compare it with the NTAP, as from our perspective, that had a much smaller reach and much less importance than the CMS ruling. Arguably.

Ed Hall
52:25 - 52:47

Okay, perfect. And then maybe just, I mean, I think maybe it's an obvious question, but I just wanted to clarify it from you. I mean, with these reimbursement changes, what do you see as the greater impact for your business? Is it your surgeon recruitment or is it greater surgeon utilization? I am sure it is probably a mix of both, but if there is any sort of leading indicator of either. Interesting.

Torbjörn Sköld
52:49 - 53:02

Yeah. It is both. Unfortunately, we wish we had the data to say that it is more of this than the other. However, no matter how we analyze this, it's both. And it is as positive on both.

Ed Hall
53:04 - 53:08

Okay. Perfect. Um very clear. Thank you very much.

Operator
53:11 - 53:16

The next question comes from Matthias Thorn from Bremer and Partners. Please go ahead.

Matthias Thorn
53:18 - 53:42

Hi. Good morning. Thank you very much for taking my questions. Congratulations on the DRG decision and on the SOLARIO study results. I would be interested to hear when you discuss it with surgeons, how do you describe the findings across the carriers in the trial, and the investigators looked at the outcome by carrier type. That is my first question.

Torbjörn Sköld
53:44 - 54:01

Okay. Very good. So if we start with the carrier types, do you want to start with that one? Dr. Michael Diefenbeck, in terms of which carrier types were included, what can the SOLARIO study actually say related to the products? How was the study designed?

Dr. Michael Diefenbeck
54:03 - 55:07

Yes, sure. Thanks for the question. It is a practical study. So, it was not focused on one single antibiotic-eluting bone graft substitute or even PMMA. So, the bone cement was included in the study. This is a study focusing on a total of 17 different products. And this is what I meant in the beginning. It is practical for the class of local antibiotics. So far, there are no subanalyses published which show the differences. And this is not what the study was designed for. It is not intended to identify the performance of one single antibiotic. It focuses on the group. So the task was to show that if local antibiotics are used, the systemic duration can be shortened.

Torbjörn Sköld
55:08 - 55:44

Correct. So it is definitely not a CERAMENT study. Clinically and scientifically, you cannot draw any conclusions on whether CERAMENT performed better or worse than the other products. However, what you can say is that it clearly indicates that you can reduce the duration of systemic antibiotics. And then you can also look at the number of patients that had CERAMENT G or V, and that was 70% of the total population in the study.

Matthias Thorn
55:46 - 58:44

Thank you very much. I would like to bring up a topic. There was recently a peer-reviewed article in the Journal of Bone and Joint Surgery, where some researchers had effectively reanalyzed the foundational study, Stravinsky from 2016, a foundational study from which BONESUPPORT has repeatedly cited the sustained antibiotic release properties of CERAMENT. This was done by the researchers obtaining the data from this study and then disproving them through a quite robust mathematical analysis. So not necessarily from any animal model, as has been cited before. Now, the reason I ask is that, while this may or may not be correct, on that basis, the product would effectively function as a bone void filler with a short but potent pulse. And presumably, outcomes would be much more driven by debridement quality, soft tissue coverage, and systemic therapy. Now, so far, we have not heard the company publicly comment on this, nor have I seen any analyst write about this, which is surprising in itself. So I would like to ask; I am aware that one of your board members wrote a letter commenting on this, but it only touched the abstract and it did not in any way refute the principal conclusion of these concise and mathematical arguments that challenged the elution property of CERAMENT. So I was wondering if the company could publicly respond to how they stand on this. I shall add that in discussions we have had with US surgeons and others, one of the principal qualities brought up regarding CERAMENT is precisely the perception of a unique elution profile. And I should also add that it's very evident that the company, including the CEO, you have commented on this on many occasions, recently at the Capital Markets Day of 2026, where a large passage was devoted to the sustained elution properties of CERAMENT. So, if you don't mind, how important is this for the customer proposition of CERAMENT G and CERAMENT V, respectively? And to what extent is this conclusion valid? That has now been brought up in the recent JBJS study. Thank you.

Unknown 2
58:45 - 58:47

Thank you for the question, Matthias.

Torbjörn Sköld
58:47 - 63:09

And that was a comprehensive background. So let's break it down. And first of all, for those of you who are not informed of which study this relates to, it is the so-called mouse study, published by a group in Aarhus in the publication of the Journal of Bone and Joint Surgery. The study was published in mid-August. And I think it is very relevant to bring up that the majority of the authors are not only part of the university. They are also part of a company that is called Precision Antibiotics. They have their own technology related to antibiotics and antibiotic elution. The technology is called Carbazole. We know the company really well and we have been made aware of this study early on. Now, I will start with the clinical relevance or how we see the clinical relevance of this. And then Dr. Michael Diefenbeck will comment on our views on that study. So first of all, from a commercial point of view, what we have seen is that we see very limited feedback or questions from the market on this. Very few. That is number one. Number two, the reason why we believe it is commercially not really relevant is simply due to the fact that it is a preclinical study done on mice where they have used CERAMENT off-label, meaning not in a way that the product is intended to be used in soft tissue in mice and where they have used very small amounts of the product compared to the amounts. That would be the typical case for when the product is used in patients. So that summarizes why we simply do not think that this study has any meaningful clinical relevance to CERAMENT. That is fundamental. And then, if we go to the next steps. What is important when we sell our products is not so much preclinical data. We stopped using preclinical data to sell our products. So, actually, we have never used preclinical data to sell our products. What matters to customers is the clinical data in general, and specifically by segment and by indication. So it's really the clinical data that is important. I think another good data point to keep in mind is, for example, when this study was presented at EBJIS, what was the feedback from the audience, including us and Professor McNally from the SOLARIO trial? I think that is important feedback. So that is the statement that we have from our side. Now, from a more clinical and scientific point of view, Dr. Diefenbeck, would you be happy to share your thoughts? Sure.

Dr. Michael Diefenbeck
63:09 - 65:15

I mentioned already very important points. Looking at the study, it had two parts: bench testing and an animal study. And as mentioned already in the animal study, the bone void filler was tested in soft tissue, which is not indicated for use. And of course, it should be obvious that the device needs to be tested according to the indication. Then, to put this on a more general basis. If we. If we look at what testing you can do with bone void fillers. With bone void fillers, you would start in a lab with bench tests. For example, you would look at the mechanical properties, the setting time, and elution. The next step would be the biocompatibility, or now called biological evaluation, where you test against cells or bacteria. Then you come to small animal models. This is the area where the mouse study was done. The next step is large animal models. And then, of course, clinical studies, which range from case reports to randomized controlled trials. So, this is a very early stage of research. Now, if you want to start in a lab and compare the elution and the concentration of implants, you need to test, of course, the same volumes of the test substance and the liquid. And this has not been done. The volumes tested were completely different, and very small sizes were used in the publication. So it is not comparable to what has been tested before. And then as you already said. A mathematical model was provided without any measurements. As I mentioned before, the mathematical model precedes bench testing. So, very early results. So as Torbjörn Sköld said, there is no impact on the clinical performance of the product.

Torbjörn Sköld
65:16 - 65:18

Thank you. Next question, please.

Operator
65:19 - 65:39

The next question comes from Eric Cassel from Danske Bank. Please go ahead. There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Torbjörn Sköld
65:39 - 66:31

Very good. Thank you. Operator. Then let's go through some of the questions that we have online. The first question is, can you quantify how much of the US growth is driven by increased utilization of existing hospitals versus new hospital customers, and how much potential remains within your current hospital network? So again, we do not quantify it. We do not provide a specific split, but we can say that it is a healthy balance driven by both factors. And that is the same picture across the different segments in the US. Then the next question is regarding the US. Gross margin declined from approximately 95.3% to 94% year over year. What explains this decline and should we consider it temporary or structural?

Håkan Johansson
66:32 - 67:20

Thank you. It's a very good question, and the main reason why there is a decline in gross margin over time mainly relates to increased manufacturing costs. The market price has been extremely solid and stable over time. So, the main impact is coming from the increase in manufacturing cost. There has been some impact from US tariffs that impacted us up to now. And here we expect returns to come in in the later part of this year. . But the gross margin as reported in this quarter, and compared also in Q2, gives a good indication of a sustained gross margin in the US.

Torbjörn Sköld
67:21 - 68:36

Good. Very good. So let's see. Scroll down. Next one. US market penetration at level one trauma centers. Can you provide an update on your penetration of level one trauma centers and your estimate of how much of the addressable US market you have reached so far? Okay. We do not provide updates on a quarterly basis. We do not provide updates on the level one trauma centers. But what we can say is the numbers and the growth that we have in the quarter give a good indication of how we are doing. And in terms of how much of the addressable US market we have reached so far, I still think the numbers that we provided on the Capital Markets Day are still relevant. So, I would refer to that on that question. Then we have another question. Operating leverage and long-term profitability, with adjusted EBIT margin now above 34% and sales commissions declining as a percentage of US revenue. How do you assess the long-term EBIT margin potential while continuing to invest in market expansion? Okay.

Håkan Johansson
68:37 - 69:19

Good question. And again, I think that the question is well phrased because it is all about the long-term EBIT margin potential. And because as we have seen also during the last year, we will have periods where we invest, especially in our commercial organization and structures, that will slow down the EBIT improvement that we have seen also over time. We have not provided any guidance on the long-term potential. But I think that the gradual improvement in EBIT margin and the high level of operating leverage gives a fair indication of the long-term potential.

Torbjörn Sköld
69:19 - 69:34

Good. Then I think we have one more call, one more question on the line. Operator. I have received a message that Christopher from Carnegie is on the phone. Would you care to open the line for Christopher?

Operator
69:36 - 69:40

The next question comes from Christopher Lilienberg from Carnegie. Please go ahead.

Eric Cassel
69:43 - 70:18

Thank you very much for. I have been in the queue from the beginning. I really would like to go back to the accelerating US growth this quarter. I think you had 4 million US dollar higher sales quarter over quarter. The previous record was 2.7 million. Total 12-month rolling trend has been 2 million after the second quarter. Would you describe this as more of a temporary effect or something more sustainable going on right now?

Håkan Johansson
70:18 - 71:22

I think that, Christopher, as with any month, there is a difference to what you have seen previously. It is just one month. So I do not think that you should see this as a sustained acceleration. Somehow it is a period where we have seen less impact of the underlying mechanics as we saw in Q2 in the US, etc. . It is a period where some new accounts and new distributors have performed well in the quarter. So I think that I really look forward to continuing the discussion in future quarterly reports and seeing what that can represent in future run rates. I think that this is a strong confirmation of the smart commercial structure that we have and the potential we have. And we still have a lot of market opportunity to go after and how that will develop quarter by quarter. So let's come back to that and see.

Eric Cassel
71:24 - 71:49

Great. And then just a quick one. There was a question earlier on the call regarding the CERAMENT potential if that is approved. So do you see this as an incremental opportunity, or do you think a large part of the 20-25% of total sales will come from switching from current CERAMENT use in the US?

Torbjörn Sköld
71:49 - 71:50

It is incremental.

Eric Cassel
71:54 - 71:56

Okay, great. That is all. Thank you.

Torbjörn Sköld
71:56 - 76:44

Okay, good. Thank you, Christopher. Let's continue with the questions that we have on the chat. And then the next one is regarding R&D and CERAMENT. Given your strong cash flow and net cash position, do you see opportunities to accelerate R&D investments in CERAMENT spine applications and next-generation products without requiring additional shareholder capital? And can you provide an update on the remaining FDA regulatory steps for CERAMENT? Okay. I will start with the last part and then we will get into the other. So the last remaining steps on CERAMENT are very much related to that. We have now submitted the package. The FDA is currently reviewing it. We stay in contact, we stay in dialogue, and we look forward to what they will say. We expect a formal reply from the FDA on this sometime in Q4 or in Q1. But those are the remaining steps. And then, assuming that we get an approval, then the next step for us is simply to produce the products, ship them to the US, and do the required trainings internally, externally, and start selling the product. So we expect a couple of months between an FDA approval and when we actually start selling the product, then if you go up a bit, sorry, you're too fast for me. I am still on the first part of that previous question. The question was, given your strong platform, do you see opportunities to accelerate R&D? I mean, regarding R&D investments in CERAMENT, we are going as fast as we can, and if we could, we would go faster, but we have the cash, so we are not cash constrained in any way. So we go as fast as we can on spine applications. Again, it comes back to that. We need the clinical evidence to be able to, number one, get the required regulatory approvals; number two, to also go to market with evidence that makes a meaningful difference. If the question relates to whether we could accelerate CERAMENT strategically, we want to focus on the antibiotic products in spine. That is where we see the big potential. CERAMENT BVF is a great product, but it is a very competitive marketplace in that segment. So our play on spine is with antibiotic, next-generation products. Um, absolutely. That is an area that we are continuing to invest in and want to go as fast as possible. We do not need any more capital. We have more cash at hand to invest in everything we need, both commercially as well as clinically, scientifically, and from a research and development point of view. So we are in a very good place.

More questions here regarding CERAMENT. Have you had any further communication or feedback from the FDA since submitting the complete response package in Q2? And has anything changed regarding your expected timeline? We remain in contact, but there is nothing new to report. Material or controversial developments with the FDA have not occurred, and the expected timeline remains as previously communicated. And then, another question here. As BONESUPPORT continues to grow and strengthen its market position, is your long-term ambition to remain an independent Swedish company, or would you consider becoming part of a larger global medtech group? And have you received any strategic approaches or acquisition interest from larger industry players? So the second question is, of course, something we cannot answer. So we leave that, and our ambition remains to stay an independent Swedish company. We are a publicly listed company, so if a larger medtech group were interested in acquiring us, they could. They could do that. That is easy. We are running this company with a purpose to make sure that our unique and innovative technology with CERAMENT reaches as many patients as possible. We think it makes a very big difference to patients, to hospitals, as well as to society. When we think about antimicrobial resistance, that is what we focus on. Our strategy does not include becoming part of a bigger company, even if they want to acquire us. We are a public company. So I do not know if that can be explained in a better way?

Håkan Johansson
76:44 - 76:46

I think you phrased it very well.

Torbjörn Sköld
76:47 - 76:57

Okay. Thank you very much. I think we've gone through all the questions on the chat as well as on the line. Then, thank you all for your interest and have a great rest of the day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…